ISPE professional development training is designed to help pharmaceutical professionals turn regulatory expectations and industry guidance into practical, efficient execution. Pierre Winnepenninckx, a long-standing ISPE member, is one of many highly qualified instructors who bring deep technical expertise and real-world experience to ISPE professional development courses. Through the two...

As the pharmaceutical industry navigates evolving regulatory expectations, emerging technologies, sustainability goals, and increasingly complex global supply networks, professionals need more than presentations and panel discussions. They need opportunities to engage directly with experts, test new ideas, and develop practical solutions they can bring back to their organizations.

AI is entering GxP-regulated environments—but simple answers are proving elusive. As guidance evolves and the technology advances rapidly, organizations face critical questions: how much control is enough, and what does enough control look like? This blog post challenges “catch-all” thinking and makes the case for a contextual, life cycle-focused approach to AI controls, prioritizing judgment,...

AI is everywhere these days—it’s impacting everything from how we plan our vacations, to what we see online, and perhaps how we attack our email inbox. How is it impacting drug development, and how are global regulatory agencies adapting to the use of AI? ISPE’s Regulatory Quality Harmonization Committee’s Asia Pacific Regional Focus Group has reviewed a few recent AI-related guidances from...

As pharmaceutical manufacturers work to deliver increasingly complex therapies while improving efficiency, sustainability, and worker safety, facilities must evolve to support entirely new approaches to drug production. Chugai Pharma Manufacturing’s FJ3 Project demonstrates how innovative facility design can help overcome long-standing manufacturing limitations while accelerating patient...

How is AI transforming pharmaceutical manufacturing and life sciences? Where are organizations successfully applying AI today? And how can professionals develop the skills needed to navigate an industry that is rapidly evolving through digital innovation?

As pharmaceutical manufacturers face increasing pressure to bring complex therapies to market faster, the role of process engineering has become more critical than ever. From oncology and high-potency compounds to aseptic manufacturing environments, successful project execution requires a careful balance of technical expertise, regulatory compliance and operational efficiency. Drawing on more...

The ISPE Foundation Professional Development Grant program is designed to help students and recent graduates take meaningful steps toward building successful careers in the pharmaceutical and biotechnology industries. By providing financial support to attend ISPE conferences, the program connects emerging professionals with industry experts, cutting-edge knowledge, and valuable networking...

ISPE training courses are designed to help pharmaceutical professionals translate regulatory expectations into practical, effective execution. Central to that mission are instructors like Chip Bennett, whose depth of experience brings credibility and real-world perspective to the classroom.

In today’s highly regulated pharmaceutical industry, maintaining product quality and patient safety depends on more than systems and procedures. It depends on people. Specifically, it depends on how well individuals understand and apply the principles of a robust pharmaceutical quality system.

As pharmaceutical manufacturing continues its transformation through artificial intelligence (AI), automation, advanced analytics, and increasingly digital operations, one critical factor remains at the center of success: people. While new technologies are reshaping every stage of the product lifecycle, organizations are discovering that sustainable transformation depends not only on...

As the pharmaceutical industry works to reduce its environmental footprint while continuing to deliver life-transforming therapies to patients worldwide, organizations are increasingly seeking solutions that balance operational performance, sustainability, and long-term resilience. Takeda’s AHEAD – Advanced Heat Pump Demonstrator project represents a powerful example of what is possible when...

Emily Heffernan, US Director of New Process Technologies at Arcadis, is a process subject matter expert specializing in biological process and facility design. With more than 20 years of experience, her expertise spans multiple therapeutic areas, including monoclonal antibodies (mAbs), vaccines, cell and gene therapies (C&GTs), and ribonucleic acid (RNA) therapeutics.

In pharmaceutical manufacturing, product quality begins long before a medicine reaches the production line. Critical utility systems such as pharmaceutical water, pure steam, compressed air, and process gases play a direct role in manufacturing processes and frequently come into contact with products, equipment, and controlled environments. As a result, the quality of these utilities must be...

Turnover package (TOP) is one of the most critical deliverables in pharmaceutical projects. It provides complete documentation on systems, equipment, and components from supplier/service providers to construction and project teams to end users. Traditionally, TOP reviews are performed manually, requiring extensive effort from construction and commissioning and qualification (C&Q) experts...

Sanofi’s Modulus platform is redefining what pharmaceutical manufacturing can look like in an era shaped by personalized medicines, rapidly evolving therapeutic technologies, and increasing global demand for production agility. Recognized with the 2026 ISPE Facility of the Year Awards (FOYA) Innovation – Facility of the Future Category Award, Modulus represents a groundbreaking approach to...

Innovative medicines are advancing across a broad range of therapeutic modalities, from small molecules and biologics to next-generation therapies such as ATMPs, ADCs, radiopharmaceuticals, and mRNA-based products. Yet scientific breakthroughs alone are not enough. Transformative therapies only fulfill their promise when they can be manufactured reliably, scaled efficiently, navigated through...

Bayer AG’s SOLIDA-1 facility in Leverkusen, Germany, has achieved a rare distinction in the pharmaceutical manufacturing industry: winning two categories in the 2026 ISPE Facility of the Year Awards (FOYA). Recognized for both Operations – Operational Excellence and Pharma 4.0™, SOLIDA-1 demonstrates how digital transformation, modular facility design, and autonomous manufacturing can work...